Mereo BioPharma Group plc - Sponsored ADR MREO
0.37
0.03
8.82%
as of 25 Sep
- Market cap
- $54.9M
- P/E
- 0.0×
Follow MREO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | — | 0.00 | — | 0.00 | — | — | — |
P/S ratio |
0.00 | — | 0.00 | — | 0.00 | — | — | — |
P/FCF ratio |
0.00 | — | 0.00 | — | 0.00 | — | — | — |
P/Operating CF |
(8.72) | — | (44.68) | — | 0.00 | — | — | — |
P/B ratio |
1.64 | — | 6.00 | — | 0.00 | — | — | — |
Price to Tangible BV |
1.66 | — | 6.13 | — | 0.00 | — | — | — |
EV/Sales |
0.00 | — | 0.00 | — | 0.00 | — | — | — |
EV/EBITDA |
0.00 | — | 0.00 | — | 0.00 | — | — | — |
EV/Operating CF |
(0.99) | — | (12.09) | — | 2.14 | — | — | — |
EV/FCF |
(0.98) | — | (11.45) | — | 2.11 | — | — | — |
Quick Ratio |
9.53 | 5.04 | 6.05 | 2.80 | 7.70 | 2.95 | 0.60 | 1.74 |
Current Ratio |
10.46 | 5.40 | 6.72 | 3.09 | 7.92 | 3.47 | 1.02 | 2.13 |
Net Debt/EBITDA |
1.04 | 1.49 | 1.90 | 1.26 | 3.94 | 0.20 | (0.11) | 0.17 |
Debt/Assets |
0.00% | 0.00% | 6.61% | 0.00% | 11.38% | 25.64% | 23.73% | 31.93% |
Debt/Equity |
0.00 | 0.00 | 0.09 | 0.00 | 0.16 | (1.08) | 0.51 | 0.66 |
Asset Turnover |
0.01 | 0.00 | 0.14 | 0.00 | 0.39 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.74 | 0.76 | 0.72 | 1.16 | (0.41) | 0.17 | 1.32 | 0.72 |
Capex/Depreciation |
(0.51) | (1.20) | (0.74) | (0.07) | (0.66) | 1.13 | (0.01) | (0.88) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (82.21%) | (77.58%) | (57.81%) | (48.98%) | 34.38% | (1,305.77%) | (93.52%) | 0.00% | |
| (68.48%) | (60.54%) | (40.95%) | (33.61%) | 13.74% | (219.76%) | (44.45%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (161.74%) | 0.00% | (55.60%) | (82.38%) |
Return on Tangible Assets |
(102.50%) | (70.71%) | (53.89%) | (82.18%) | 14.25% | (719.75%) | (287.61%) | (173.44%) |
Average Days of Receivables |
0.00 | — | 0.00 | — | 22.30 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
3,553.20% | 0.00% | 174.18% | 0.00% | 64.61% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
4,601.60% | 0.00% | 184.24% | 0.00% | 43.70% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.02 | 0.00 | 0.19 | 0.50 | 0.51 | 0.49 |
Share Based Compensation of Revenue |
1,519.60% | 0.00% | 49.24% | 0.00% | 9.06% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.60 | — | 0.16 | — | 0.00 | — | — | — |
Graham Number |
0.00 | — | 0.00 | — | 0.00 | — | — | — |
Earnings Yield |
(62.55%) | — | (8.02%) | — | (8.02%) | — | — | — |
Free Cash Flow Yield |
(46.73%) | — | (7.36%) | — | 0.00% | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.08 | 0.00 | 0.48 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.19) | (0.22) | (0.16) | (0.40) | (0.07) | (0.54) | (3.28) | (2.17) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | (0.01) | 0.03 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.20) | (0.23) | (0.16) | (0.40) | (0.07) | (0.50) | (3.28) | (2.17) |
Cash per Share |
0.26 | 0.47 | 0.44 | 0.57 | 1.23 | 0.44 | 1.17 | 2.58 |
Shareholders Equity per Share |
0.26 | 0.41 | 0.38 | 0.43 | 1.15 | (0.28) | 2.87 | 3.07 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.26 | 0.41 | 0.38 | 0.43 | 1.15 | (0.28) | 2.87 | 3.07 |
Free Cash Flow |
(31.29) | (33.53) | (21.55) | (48.83) | (7.78) | (34.07) | (58.68) | (30.93) |
Working Capital |
40.72 | 60.92 | 54.27 | 50.82 | 119.33 | 27.17 | 0.71 | 24.45 |
Capital Expenditures |
(0.32) | (0.70) | (0.42) | (0.01) | (0.58) | 2.32 | (0.03) | (0.04) |
Net Current Asset Value |
40.02 | 59.34 | 47.80 | 49.19 | 83.75 | (61.88) | (20.12) | (0.01) |
EV/EBIT |
0.00 | — | 0.00 | — | 0.00 | — | — | — |
Capex to Sales |
0.64 | 0.00 | 0.04 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
(8,375.60%) | 0.00% | (294.66%) | 0.00% | 34.90% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | — | 0.00 | — | 0.00 | — | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
4.54 | 2.26 | 1.40 | 0.33 | 0.25 | 1.02 | 0.14 | 0.25 |
Cash ROIC |
(37.98%) | (25.30%) | (19.17%) | (41.29%) | (3.95%) | (121.40%) | (74.55%) | (28.47%) |
Accounts Receivable Turnover |
0.00 | — | 0.00 | — | 18.57 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.07 | 0.00 | 0.88 | (0.33) | 6.38 | 0.00 | 0.00 | — |
Inventory Turnover |
0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
3,658.23 | 0.00 | 332.67 | (1,112.20) | 50.93 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | — | 2.70 | 2.16 | 1.40 | — |
Average Payables |
1.89 | 2.39 | 2.92 | 3.46 | 3.86 | 6.20 | 7.11 | — |
Average Assets |
61.15 | 71.44 | 71.96 | 125.62 | 127.33 | 95.61 | 100.09 | — |
Average Common Equity |
50.94 | 55.75 | 50.97 | 86.21 | 50.89 | 16.09 | 47.57 | — |
Columns are period end dates